Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis

Plain-language summary

This study aims to develop a targeted RNA sequencing method that may help in diagnosing amyotrophic lateral sclerosis (ALS). Patients referred for genetic testing for ALS, and people with familial hypercholesterolemia for the control group, may take part. It is a non-phase study and is currently enrolling participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Centre Hospitalier Universitaire de Nīmes

Intervention

RNA sequencing

Start date

11/22/2023

Estimated completion

5/1/2027

Countries

France

Related genes

Locations

• Bordeaux, France
• Clermont-Ferrand, France
• Lyon, France
• Marseille, France
• Montpellier, France
• Nîmes, France
• Toulouse, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Have a prescription for a genetic diagnosis of ALS (or familial hypercholesterolemia for the control cohort)
* Have given their informed consent for the genetic study and the biobank
* The patient must be a member or beneficiary of a health insurance plan

Exclusion Criteria:

* The patient is under safeguard of justice or state guardianship